nivolumab,ipilimumab,cabozantinib
bms
['nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', 'cosmic313', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo']
kicking off day 3 at #gu23 with an update on #cosmic313 study data presented by from 
Leading cancer centre committed to outstanding patient care and innovative research. Follow for first look of our work!